sacituzumab
gilead sciences
['mbc', 'sacituzumab', 'sacitu, govi', 'bcsm']
#esmo22: improvement in overall survival with sacituzumab govitecan (vs tpc) for pre-treated hr+ mbc, median os: 14.4m vs 11.2m (hr: 0.79). nice presentation #oncoalert #bcsm 
Medical Oncologist, MGH, Harvard Medical School. Interested in cool science, technology, patient stories, and therapies against cancer.